Ontrak (NASDAQ:OTRK) Stock, Quote.Headers.trade-ideas

Ontrak

Ontrak Inc is an artificial intelligence (AI)-powered and technology-enabled behavioral healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. The Company's technology-enabled platform utilizes claim-based analytics and predictive modeling to provide analytic insights throughout the delivery of our personalized care program. The company's integrated, technology-enabled OntrakTM solutions, a component of the PRE platform, are designed to treat members with behavioral conditions that cause chronic medical conditions such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure.

Earnings

News

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

EDBL

INVO

LGVN

OTRK

SAGE

VNDA

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday.

The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21. The S&amp;P 500 also fell, dropping, 0.34% to 5,034.17.

Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views

Movers

ADPT

ADSK

ALXO

ASML

AWIN

CGEM

CHRO

CXAI

DFLI

DXYZ

DYNT

EZGO

FNCH

FWRD

HUBC

IBKR

ISUN

JBHT

MSTR

PLCE

PRTG

RANI

SBFM

SINT

SMXT

SNDL

SPEC

SXTC

TCON

TPET

VIAO

VIRX

WISA

Shares of  The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday.

The Dow traded down 0.32% to 37,678.27 while the NASDAQ fell 1.16% to 15,681.95. The S&amp;P 500 also fell, dropping, 0.74% to 5,013.98.

Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge

Ontrak Inc

Canaccord Genuity analyst Joseph Vafi initiates coverage on Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy rating and announces Price Target of $16.

Price Target

Initiation

Analyst Ratings

Core Scientific, Inc. - Class A Common Stock

CORZ

Canaccord Genuity Initiates Coverage On Core Scientific with Buy Rating, Announces Price Target of $16

Piper Sandler analyst Korinne Wolfmeyer maintains Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) with a Neutral and raises the price target from $20 to $21.

KVUE

Piper Sandler Maintains Neutral on Kenvue, Raises Price Target to $21

Biotech

General

TOVX

Theriva Biologics Reaches Target Patient Enrollment In VIRAGE Phase 2b Trial Of VCN-01 With Gemcitabine/Nab-Paclitaxel For Metastatic Pancreatic Cancer Treatment, Conducted Across 15 Sites In Spain And USA

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/09/20/final-trades-samsara-constellation-energy-aptiv-and-the-indy.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management said Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) <a href="https://www.benzinga.com/quote/IOT/earnings">hit an all-time high on Friday.</a>
On Sept. 5, Samsara reported quarterly earnings of 5 cents per share which beat the analyst consensus estimate of 1 cent per share. The company reported quarterly sales of $300.20 million which beat the analyst consensus estimate of $289.54 million.
Stephen Weiss of Short Hills Capital Partners picked iShares India 50 ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDY#NASDAQ">INDY</a>), saying declining interest rates are good for emerging market economies.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage her</a><a href="https://www.benzinga.com/premarket/">e</a>
Jenny Van Leeuwen Harrington of Gilman Hill Asset Management said Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) trades at 9.5 times earnings, with 20% earnings growth over the next three years.
On Sept. 20, Wells Fargo analyst Colin Langan upgraded the rating for Aptiv from Equal-Weight to Overweight and raised the price target from $78 to $87.
Joseph M. Terranova of Virtus Investment Partners named Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) as his final trade.
On Sept. 20, Constellation Energy announced it signed a 20-year power purchase agreement with Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>). The deal entails the launch of the Crane Clean Energy Center (CCEC) and the restart of Three Mile Island Unit 1, which was <a href="https://www.benzinga.com/markets/equities/24/09/40957437/microsoft-taps-constellation-for-20-year-carbon-free-power-3-400-jobs-coming-to-pennsylvania">closed five years ago.</a>
Price Action:
<ul>
<li>Samsara gained 3.8% to close at $49.39 during Friday's session.</li>
<li>Aptiv shares fell 1% to settle at $69.84 on Friday.</li>
<li>iShares India 50 ETF gained 1.2% during Friday's session.</li>
<li>Constellation Energy shares jumped 22.3% to close at $254.98 on Friday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in">Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>
Image courtesy of Samsara

Long Ideas

Media

APTV

INDY

MSFT

Samsara, Aptiv, Constellation Energy And More On CNBC's 'Final Trades'

Matthews International Corporation (NASDAQ GSM: MATW) (the "Company") today announced a proposed private offering of senior secured second lien notes due 2027 (the "Notes"). At or prior to the closing of the offering of the Notes, the Company intends to amend its senior credit facility to, among other things, permit the Notes to be secured by a second priority lien on substantially all of our and certain of our domestic subsidiaries' assets, and the Company and certain of its domestic subsidiaries intend to enter into a second amended and restated pledge and security agreement pursuant to which the Company and such subsidiaries will grant to the secured parties under the senior credit facility a first priority lien on substantially all of the Company's and such subsidiaries' assets.
The Company intends to use the net proceeds of the offering, together with borrowings under the Company's senior credit facility, to redeem all of its outstanding 5.25% senior notes due December 1, 2025 (the "Existing 2025 Notes") on or about October 25, 2024, and to pay accrued and unpaid interest on the Existing 2025 Notes to, but not including, the date of redemption, and to satisfy and discharge the indenture governing the Existing 2025 Notes.

Offerings

MATW

Matthews International Announced A Proposed Private Offering Of Senior Secured Second Lien Notes Due 2027

Jabil Expands Silicon Photonics Capabilities At Ottawa Site To Support New Product Introductions For Hyperscalers And AI Data Centers, Set To Roll Out In Q4 2024

Morgan Stanley analyst David Arcaro maintains Public Service Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>) with a Overweight and raises the price target from $83 to $95.

Morgan Stanley Maintains Overweight on Public Service Enterprise, Raises Price Target to $95

Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (Nasdaq:&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4260606-1&amp;h=4181839075&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Finnovative-eyewear-inc-announces-exercise-of-warrants-302236683.html%23financial-modal&amp;a=LUCY">LUCY</a>), the developer of smart eyewear under the Lucyd&#xAE;, Nautica&#xAE;, Eddie Bauer&#xAE; and Reebok&#xAE; brands, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 263,160&nbsp;shares of the Company's common stock originally issued by the Company on&nbsp;May 29, 2024, each having an original exercise price of&nbsp;$9.50&nbsp;per share, at an exercise price of&nbsp;$9.875&nbsp;per share. The closing of the warrant exercise transaction is expected to occur on or about&nbsp;September 24, 2024, subject to satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-279873).
The gross proceeds to the Company from the exercise of the warrants are expected to be approximately&nbsp;$2.6 million, prior to deducting placement agent fees and offering expenses. The Company expects to use the net proceeds from the transaction for working capital and general corporate purposes.

LUCY

Innovative Eyewear Announces Exercise Of Warrants For $2.6M Gross Proceeds For The Immediate Exercise Of Certain Outstanding Warrants To Purchase An Aggregate Of 263,160 Shares Of Common Stock Originally Issued By The Company On May 29, 2024, Each Having An Original Exercise Price Of $9.50 Per Share, At An Exercise Price Of $9.875 Per Share

Cantor Fitzgerald analyst Prakhar Agrawal reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Overweight.

Reiteration

MLTX

Cantor Fitzgerald Reiterates Overweight on MoonLake

Alaska Airlines Expands Cargo Division Following Hawaiian Airlines Merger, Names Ian Morgan VP Of Cargo And Jason Berry Executive VP Of Cargo For Alaska Air Group

CORRECTION: Bernstein analyst Daniel Roeska downgrades General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) from Outperform to Market Perform and announces $53 price target (Analyst Name Updated - Originally Published on 23rd Sept 2024).

Downgrades

CORRECTION: Bernstein Downgrades General Motors to Market Perform, Announces $53 Price Target (Analyst Name Updated - Originally Published on 23rd Sept 2024)

KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) will release earnings results for its third quarter, after the <a href="https://www.benzinga.com/quote/KBH/earnings">closing bell on Tuesday</a>.
Analysts expect the Los Angeles-based company to report quarterly earnings at $2.06 per share. That&#8217;s up from $1.80 per share in the year-ago period. KB Home projects quarterly revenue of $1.73 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Sept. 19, Bank of America Securities analyst Rafe Jadrosich maintained KB Home with a Neutral rating and raised the price target from $75 to $90.
With the recent buzz around KB Home, some investors may be eyeing potential gains from the company's dividends. As of now, KB Home has a dividend yield of 1.15%. That&#8217;s a quarterly dividend amount of 25 cents a share ($1.00 a year).
To figure out how to earn $500 monthly from KB Home, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by KB Home's $1.00 dividend: $6,000 / $1.00 = 6,000 shares
So, an investor would need to own approximately $523,380 worth of KB Home, or 6,000 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.00 = 1,200 shares, or $104,676 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
KBH Price Action: Shares of KB Home fell 2.6% to close at $87.23 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in">Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>
Image: Shutterstock

How To Earn $500 A Month From KB Home Stock Ahead Of Q3 Earnings

Macro Economic Events

Economics

Federal Reserve

Fed's Kashkari Says Penciled In 50 Basis Points More Cuts In 2024

AirBaltic Signs Long-Term EngineWise Maintenance Agreement With Pratt & Whitney For GTF Engine Fleet, Linking Costs To Engine Utilization

LTRN

Lantern Pharma Receives Three FDA Rare Pediatric Disease Designations For LP-184 In Malignant Rhabdoid Tumors, Rhabdomyosarcoma, And Hepatoblastoma, Bringing Total To Four RPDDs

WIIM

SPRC

SciSparc shares are trading higher after the company received FDA approval to initiate a Phase IIb clinical trial of SCI-110 for the treatment of Tourette syndrome.

Gorilla Technology Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>)&nbsp;("Gorilla" or the "Company") and CS Energy Technology Co., Ltd., one of Asia's leading energy infrastructure providers, have announced a strategic cooperation agreement. This collaboration marks a transformative step in developing innovative solutions for smart and green cities across Thailand and Southeast Asia to shape a sustainable future.

GRRR

Gorilla Technology And CS Energy Form AI-Powered Strategic Partnership To Accelerate The Rise Of Smart & Green Cities Across Thailand And Southeast Asia

SciSparc Receives FDA Approval To Initiate Phase IIb Clinical Trial Of SCI-110 In Tourette Syndrome Treatment

U.S. stocks settled higher on Friday, with the Dow Jones index settling at a record high during the session. The US Federal Reserve, on Wednesday, slashed interest rates by 50 basis points Wednesday at its September Federal Open Market Committee meeting, lowering the federal funds rate to a range of 4.75% to 5%.
All three major indices recorded weekly gains, with the S&amp;P 500 gaining around 1.4% and adding more than 19% in 2024. The Dow gained around 1.6% last week, while the tech-heavy Nasdaq jumped around 1.5% during the week.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Zachary Fadem
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Maintained an Equal-Weight rating on Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) and raised the price target from $160 to $165 on Sept. 20. This analyst sees around 3% downside in the stock.</li>
<li>Recent News: On Sept. 19, Darden Restaurants reported weaker-than-expected first-quarter financial results.</li>
</ul>
Analyst: Sam Reid
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained an Overweight rating on Ferguson Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) and cut the price target from $250 to $225 on Sept. 18. This analyst sees around 13% upside in the stock.</li>
<li>Recent News: On Sept. 17, the company reported net sales of $7.946 billion, which was 1.4% higher year over year, missing the consensus of $7.993 billion.</li>
</ul>
Analyst: Mark Hughes
<ul>
<li>Analyst Firm: Truist Securities</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained a Hold rating on Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) and raised the price target from $265 to $275 on Sept. 20. This analyst sees around 0.4% downside in the stock.</li>
<li>Recent News: On July 25, Arthur J. Gallagher reported better-than-expected second-quarter revenue results.</li>
</ul>
Analyst: Josh Sullivan
<ul>
<li>Analyst Firm: Benchmark</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Reiterated a Buy rating on Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) with a price target of $10 on Sept. 18. This analyst sees more than 9% gain in the stock.</li>
<li>Recent News: On Sept. 17, Intuitive Machines announced it was awarded a NASA Near Space Network contract for communication and navigation services, with a maximum potential value of $4.82 billion.</li>
</ul>
Analyst: Aaron Raker
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained an Overweight rating on Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) and cut the price target from $190 to $175 on Sept. 18. This analyst sees around 92% upside in the stock.</li>
<li>Recent News: On Sept. 17, Micron announced the availability of the Crucial P310 2280 Gen4 NVMe solid-state drive (SSD) which expands Micron's P310 portfolio to address PCs, laptops and PlayStation 5. The company said a version with a heatsink will be released in the coming months, suited for use with PlayStation 5 and desktop gaming PCs.</li>
</ul>
Read More:<a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in">Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>

Pre-Market Outlook

FERG

LUNR

This Analyst With 85% Accuracy Rate Sees Around 92% Upside In Micron - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Monday.
Shares of Jin Medical International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) fell sharply in today's pre-market trading after jumping around 55% on Friday.
Jin Medical International shares dipped 23.5% to $3.12 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Jin Medical International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares dipped 21.5% to $3.20 in pre-market trading after jumping around 55% on Friday.</li>
<li>Primega Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) shares declined 10.3% to $15.00 in pre-market trading after gaining more than 5% on Friday.</li>
<li>James Hardie Industries plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) shares slipped 6% to $39.49 in pre-market trading after gaining more than 8% on Friday.</li>
<li>Korea Electric Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEP#NYSE">KEP</a>) shares declined 5.4% to $7.77 in pre-market trading.</li>
<li>Genmab A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) shares fell 4.3% to $24.44 in pre-market trading after declining around 4% on Friday.</li>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) shares declined 4.1% to $6.10 in pre-market trading following a 9% decline on Friday.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares fell 2.8% to $5.13 in pre-market trading after declining over 2% on Monday.</li>
</ul>
Now Read This:
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in"> Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>

GMAB

PGHL

RZLV

ZJYL

Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
For most investors, the goal is to buy low and sell high. Then a megatrend like artificial intelligence (AI) comes along, and the tendency to chase stocks higher kicks in. FOMO (fear of missing out) can affect even patient investors. However, while split-adjusted Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/" target="_blank">NVDA</a>) looks inviting, it may be time to look for the most undervalued AI <a href="https://investorplace.com/stock-types/penny-stocks/" target="_blank">penny stocks</a>. This is where the real action may come from.



<a href="https://investorplace.com/stock-types/penny-stocks/">Penny stocks</a> can be volatile, and many are cheap for a reason. Specifically, many companies have poor fundamentals that will likely prevent them from living up to their potential. That is particularly true in an emerging sector like artificial intelligence (AI). Many companies have entered the market, with the only compelling story being that they offer AI in one form or another.



Moving forward, the question is which companies can monetize AI meaningfully. The payoff may not be immediate. But if you have patience, here are three of the most undervalued <a href="https://investorplace.com/industries/technology/artificial-intelligence/" target="_blank">AI stocks</a> you can consider.



<h2>SoundHound AI (SOUN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/02/shutterstock_1705231162-300x169.jpg" alt="SOUN stock: SoundHound's Headquarters exterior featuring a sign with the company's logo in the foreground and a parking lot and building in the background."><div>Source: Tada Images / Shutterstock</div></div>Can you put a stock in a group of the most undervalued AI penny stocks when it&rsquo;s up 59% in the past 12 months and 125% in 2024? If the company is SoundHound AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/" target="_blank">SOUN</a>), that appears to be the case.



SoundHound offers its customers a &ldquo;voice AI platform that&rsquo;s revolutionary in its ability to understand speech and yet beautifully simple in how it responds.&rdquo; The <a href="https://www.soundhound.com/" target="_blank">company&rsquo;s goal</a> is to make conversational intelligence more human. And it&rsquo;s collecting an impressive roster of customers.



But this is still a small-cap company with just a $1.85 billion market cap. And even though SoundHound is growing revenue impressively, it&rsquo;s not yet profitable. That&rsquo;s one reason that the stock has fallen sharply after climbing to nearly $9 per share in mid-March 2024 after Nvidia announced it was <a href="https://investorplace.com/market360/2024/06/7-growth-stocks-to-buy-in-june-for-great-gains/" target="_blank">buying a piece of the company</a>.



If you want to invest in SOUN stock, you must be aware that it carries 23% short interest, which has grown significantly in the past month. In that time, the stock has been down 6.2%, which has extended its 20% decline in the last three months.



<h2>BigBear.ai (BBAI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/bbai1600-300x169.png" alt="BigBear.ai (BBAI) is a leading provider of high-speed decision-making technologies. They specialize in AI-driven analytics and solutions for critical missions"><div>Source: MacroEcon / Shutterstock.com</div></div>BigBear.ai (NASDAQ:<a href="https://investorplace.com/stock-quotes/bbai-stock-quote/" target="_blank">BBAI</a>) stock is down 36% in 2024, but this is a recent development. As recently as March 2024, the stock was over $4 a share, which is nearly triple the company&rsquo;s current price.



BigBear.ai is in the Big Data business. It&rsquo;s a growing sector, which makes it concerning that the company is not growing its revenue and remains unprofitable. BBAI stock is down 43% in the last three months, and with short interest around 16%, it could fall further.



The hope comes from the company&rsquo;s recent <a href="https://bigbear.ai/newsroom/bigbear-ai-completes-pangiam-acquisition/" target="_blank">acquisition of Pangiam</a>, which will expand BigBear&rsquo;s core capabilities. Ideally, this will allow it to expand its customer base. That will take time, and many investors may feel there are better options.



I can only go by what the analysts say. BBAI stock is covered by six analysts, which is fairly impressive for such a small company. <a href="https://www.tradingview.com/chart/aMepJfAr/?symbol=NYSE%3ABBAI&amp;utm_source=www.marketbeat.com&amp;utm_medium=widget&amp;utm_campaign=chart-logo&amp;utm_term=NYSE%3ABBAI" target="_blank">Three of those six have a Strong Buy rating</a> on the stock, and the consensus price target of $3.63 represents a 158% upside from its closing price on June 11, 2024.



<h2>Ontrak (OTRK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/healthcare-1600-300x169.jpg" alt="Nurse holding a tablet with icons representing different aspects of healthcare and healthcare data representing CANO stock. Healthcare Tech Stocks. Healthcare Stocks to Buy"><div>Source: metamorworks / Shutterstock</div></div>Ontrak (NASDAQ:<a href="https://investorplace.com/stock-quotes/otrk-stock-quote/" target="_blank">OTRK</a>) is a true penny stock. It is a tiny company with a market cap of just over $11 million. However, the AI- and technology-enabled behavioral health company is using AI to augment personal care and improve patient outcomes. For its customers, Ontrak forecasts cost savings and a higher return on investment.



The key to the company&rsquo;s bullish thesis is the nationwide adoption of its <a href="https://ontrakhealth.com/" target="_blank">WholeHealth+ program</a>. Currently, Ontrak is accepted in 30 states and the District of Columbia.



However, like many small-cap companies, Ontrak is not profitable, revenue is not growing significantly, and the company has little cash on hand. As evidence of that last point, the company announced an 8-for-1 reverse stock split in 2023. Those can be the kiss of death for small companies. Nevertheless, if you&rsquo;re looking for an under-the-radar pick among the most undervalued AI penny stocks, Ontrak may be a sneaky choice.



On the date of publication, Chris Markoch did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines.</a>
<div>Chris Markoch is a freelance financial copywriter who has been covering the market for over five years. He has been writing for InvestorPlace since 2019.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/most-undervalued-ai-penny-stocks-3-names-for-patient-investors/">The 3 Most Undervalued AI Penny Stocks to Buy in June 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 3 Most Undervalued AI Penny Stocks to Buy in June 2024

Former Ontrak CEO found guilty of insider trading

Finally, ATI Physical Therapy Within Striking Distance Of Profitability

Roth MKM analyst Jonathan Aschoff maintained a Buy rating on Ontrak (OTRK – Research Report) today and set a price target of $4.00. The company's s...

Roth MKM Remains a Buy on Ontrak (OTRK)

Ontrak Non-GAAP EPS of -$0.09, revenue of $2.45M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ontrak (NASDAQ:<a href="https://investorplace.com/stock-quotes/otrk-stock-quote/">OTRK</a>) just reported results for the second quarter of 2024.<ul><li>Ontrak reported earnings per share of -9 cents. This was above the analyst estimate for EPS of -10 cents.</li><li>The company reported revenue of $2.45 million.</li><li>This was 5.73% worse than the analyst estimate for revenue of $2.60 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/otrk-stock-earnings-ontrak-for-q2-of-2024/">OTRK Stock Earnings: Ontrak Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OTRK Stock Earnings: Ontrak Beats EPS, Misses Revenue for Q2 2024

Ontrak, Inc. (OTRK) Q2 2024 Earnings Call Transcript

Ontrak to conduct 1-for-15 reverse stock split

Ontrak ( ($OTRK) ) has issued an update. Ontrak, Inc. has announced a 1-for-15 reverse stock split, slated to be effective at the start of trading ...

Ontrak Implements Reverse Split to Satisfy Nasdaq Requirements

These are the upcoming stock splits for the week of September 23 to September 27, based on&nbsp;TipRanks' Stock Splits Calendar. A stock split is a...

Upcoming Stock Splits This Week (September 23 to September 27) – Stay Invested

ATIP

BBAI

EVTL

MPLN

NVDA

OTRKP

RSLS

SOUN

TRAW

Press Releases

Ontrak Health Finalizes Study Results for Prominent Health Plan's Medicaid Members with WholeHealth+ Program

Ontrak Health to Report 2024 Second Quarter Financial Results on August 8, 2024

Ontrak Announces New Contract with Large Northeast Regional Health Plan

Ontrak Health Announces Expected 2024 Second Quarter Financial Results

Ontrak Health Secures HITRUST CSF® Certification for 2024, Affirming Commitment to Data Security and Compliance

Ontrak Health and MosaicVoice Partner to Revolutionize Healthcare with AI-Powered Voice Technology

Ontrak Health Launches Innovative Solution to Improve Quality Measures and Boost Performance Scores

Ontrak Health to Present at National Healthcare Industry Events

Ontrak Health Demonstrates Significant Improvement in Members' Quality of Life from ReQoL Mental Health Assessment

Ontrak, Inc. Announces Reverse Stock Split

Accolade

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

American Shared Hospital Services Common Stock

American Shared Hospital

ATI Physical Therapy, Inc. Class A Common Stock

ATI Physical Therapy

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

CareMax

DocGo

Enhabit

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

23andMe Holding

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

National Research Corporation - Common Stock

National Research

Nutex Health

Performant Financial Corporation - Common Stock

Performant Finl

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Psychemedics

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

Talkspace

Vivos Therapeutics

Roth MKM

Canaccord Genuity

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Ontrak

Ontrak (OTRK) Forecast

Ontrak (NASDAQ:OTRK) Stock, Quote.Headers.trade-ideas